Compare ADUS & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADUS | AZTA |
|---|---|---|
| Founded | 1979 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.4B |
| IPO Year | 2009 | 1995 |
| Metric | ADUS | AZTA |
|---|---|---|
| Price | $114.55 | $35.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $138.73 | $43.60 |
| AVG Volume (30 Days) | 189.6K | ★ 787.5K |
| Earning Date | 11-03-2025 | 11-21-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.76 | N/A |
| EPS | ★ 4.66 | N/A |
| Revenue | ★ $1,346,596,000.00 | $593,821,000.00 |
| Revenue This Year | $25.50 | $6.13 |
| Revenue Next Year | $7.11 | $5.02 |
| P/E Ratio | ★ $24.65 | $70.75 |
| Revenue Growth | ★ 18.77 | 3.55 |
| 52 Week Low | $88.96 | $23.91 |
| 52 Week High | $136.72 | $55.64 |
| Indicator | ADUS | AZTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 56.05 |
| Support Level | $110.07 | $34.41 |
| Resistance Level | $116.92 | $38.22 |
| Average True Range (ATR) | 3.21 | 1.68 |
| MACD | -0.19 | 0.06 |
| Stochastic Oscillator | 39.36 | 25.52 |
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, mainly to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are medical in nature to those individuals who may require assistance during an illness or after surgery.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.